AVACEN Medical Receives CE (Conformité Européenne) Mark for Increasing Microcirculation and Treating Widespread Fibromyalgia Pain
SAN DIEGO, Aug. 4, 2017 /PRNewswire/ -- AVACEN Medical (AVACEN) announced its AVACEN 100, Class II, OTC medical device has received the CE (Conformité Européenne) Mark approval to treat widespread pain associated with fibromyalgia and increasing microcirculation. This is in addition to the temporary relief of joint pain associated with arthritis which is one of the many indications the device has been cleared for by the FDA in the USA.
The CE Mark allows AVACEN to market the AVACEN 100 to the European Union’s 28 member countries where many prescription drugs, available in the U.S., have been rejected by regulatory officials for treating fibromyalgia pain.
Fibromyalgia is characterized by chronic widespread pain. It affects approximately 200 to 400 million people worldwide according to The National Fibromyalgia Association. In Europe, the European Network of Fibromyalgia Associations (ENFA) estimates fibromyalgia affects an estimated 14 million people. It has a devastating impact on those who suffer from the disease and their personal support systems. In addition, it imposes a large economic burden on public and private healthcare providers.
The Company’s FDA-cleared AVACEN 100 uses The AVACEN Treatment Method, an entirely new concept in chronic pain treatment by noninvasively and safely infusing heat into the circulatory system to create muscular relaxation while increasing microcirculation throughout the body. Unlike other medical devices providing only local pain relief, the AVACEN 100’s unique mechanism of action offers widespread pain relief and many other benefits that are the result of increased microcirculation.
AVACEN Medical, CEO Thomas Muehlbauer, described the AVACEN 100 as: “The only OTC medical device on the market today able to provide non-invasive, rapid whole body treatment, using a single point of contact. It is the ideal drug-free and safe alternative for relief of muscle and joint pain while increasing microcirculation.” Muehlbauer added, “The most exciting aspect of CE approval is that the E.U. market has shown high demand and acceptance for innovative new alternatives to pharmaceuticals for treating chronic pain.”
CE approval for fibromyalgia treatment was based on a Clinical Evaluation Report which highlighted AVACEN’s very promising 22-person fibromyalgia study. One hundred percent (100%) positive results were recorded for the full therapeutic treatment group. The AVACEN study was conducted under a Cooperative Research Development Agreement with the U.S. Department of Veterans Affairs at the University of California San Diego Center for Pain Medicine, Perlman Medical Center and the VA Medical Center, San Diego.
The Society for Neuroscience 2013 Annual Meeting abstract program disclosed the 28-day AVACEN follow-up study produced a statistically significant reduction of over 40% in the widespread pain index and a reduction in average tender point counts from approximately 15 to 9 (11 is used for clinical assessment). Study details are published on the National Institutes of Health ClinicalTrials.gov website. The peer reviewed study report can be found at AVACEN.com/FMS.
The US Patent Office has issued 4 Patents to AVACEN and patents have been issued for China, Australia, Japan, UK, France, Germany, Spain, Sweden and Canada. Patents are pending in India and Hong Kong.
IMPORTANT NOTES: The AVACEN 100 is not for sale in the U.S. or E.U. for any non-cleared or non-approved indication mentioned in this document.
About AVACEN Medical
AVACEN Medical is dedicated to the innovation and design of safe, easy to use, noninvasive drug-free alternatives for the management of pain associated with numerous chronic and acute conditions including the temporary relief of minor muscle and joint pain and stiffness associated with arthritis and potentially other conditions that can cause joint pain, such as CRPS, Reynaud’s, and Lyme Disease. Founded in 2009, AVACEN Medical is headquartered in San Diego. Contact: Ryan Jeffcoat at (888) 428-2236 x 711 or 171010@email4pr.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/avacen-medical-receives-ce-conformite-europeenne-mark-for-increasing-microcirculation-and-treating-widespread-fibromyalgia-pain-300499753.html
SOURCE AVACEN Medical
